Combined treatment of gefitinib with MEK inhibitors was shown to be therapeutically useful in lung adenocarcinoma cells with acquired gefitinib resistance and EGFR mutations [12,32]. This evidence concerns the gene MAP2K7 and lung adenocarcinoma.